Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F-627 vs rhG-CSF for chemotherapy-induced neutropenia in breast cancer
CTR20140499Phase 2Completed
- Sponsor
- Generon
- Start
- Jun 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of efbemalenograstim alfa in neutropenia, sponsored by Generon. Started Jun 2016; status: completed.
02
Drugs
efbemalenograstim alfa
03
Conditions
neutropenia
Beyond the preview
Go deeper on CTR20140499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20140499.